TECVAYLIHCP.COM: Keyword Density Checker

Total words: 1313 | 2-word phrases: 341 | 3-word phrases: 363 | 4-word phrases: 371

PAGE INFO

Title	Try to keep the title under 60 characters (56 characters) Official HCP Website \| TECVAYLI® (teclistamab-cqyv) HCP
Description	Try to keep the meta description between 50 - 160 characters (168 characters) Learn about TECVAYLI® (teclistamab-cqyv), an injection treatment, on the official HCP website. See full Safety & Prescribing Information, including Boxed Warnings.
Keywords	Meta keywords are not recommended anymore (0 characters)
H1	H1 tag on the page (19 characters) POWER WITHIN REACH1

#	Keyword	Frequency	Density
1	get in touch	3	0.83%
2	for healthcare professionals	2	0.55%
3	hand tightly holding	2	0.55%
4	including a pi	2	0.55%
5	a pi an	2	0.55%
6	pi an immunomodulatory	2	0.55%
7	an immunomodulatory agent	2	0.55%
8	tightly holding rainbow	2	0.55%
9	relapsed or refractory	2	0.55%
10	an anticd38 monoclonal	2	0.55%
11	up for updates	2	0.55%
12	sign up for	2	0.55%
13	of differentiation 3	2	0.55%
14	and an anticd38	2	0.55%
15	cluster of differentiation	2	0.55%
16	important safety information	2	0.55%
17	or refractory multiple	2	0.55%
18	medical information center	2	0.55%
19	register to stay	1	0.28%
20	from johnsonjohnson and	1	0.28%
21	prior therapies including	1	0.28%
22	therapies including a	1	0.28%
23	anticd38 monoclonal antibody1	1	0.28%
24	yellow monoclonal antibody	1	0.28%
25	monoclonal antibody icondiscover	1	0.28%
26	antibody icondiscover the	1	0.28%
27	icondiscover the sciencearrow	1	0.28%
28	the sciencearrow icon	1	0.28%
29	bar chart iconclinical	1	0.28%
30	chart iconclinical study	1	0.28%

#	Keyword	Frequency	Density
1	a pi an immunomodulatory	2	0.54%
2	pi an immunomodulatory agent	2	0.54%
3	including a pi an	2	0.54%
4	cluster of differentiation 3	2	0.54%
5	and an anticd38 monoclonal	2	0.54%
6	relapsed or refractory multiple	2	0.54%
7	sign up for updates	2	0.54%
8	included patients who had	1	0.27%
9	had previously received at	1	0.27%
10	who had previously received	1	0.27%
11	patients who had previously	1	0.27%
12	study the study included	1	0.27%
13	study included patients who	1	0.27%
14	the study included patients	1	0.27%
15	12 study the study	1	0.27%
16	singlearm openlabel multicenter phase	1	0.27%
17	in a singlearm openlabel	1	0.27%
18	least 3 prior therapies	1	0.27%
19	prior therapies including a	1	0.27%
20	3 prior therapies including	1	0.27%
21	with rrmm in a	1	0.27%
22	therapies including a pi	1	0.27%
23	an anticd38 monoclonal antibody1	1	0.27%
24	yellow monoclonal antibody icondiscover	1	0.27%
25	monoclonal antibody icondiscover the	1	0.27%
26	antibody icondiscover the sciencearrow	1	0.27%
27	icondiscover the sciencearrow icon	1	0.27%
28	bar chart iconclinical study	1	0.27%
29	chart iconclinical study resultsarrow	1	0.27%
30	iconclinical study resultsarrow icon	1	0.27%
31	exclamation point within trianglesafety	1	0.27%
32	point within trianglesafety profilearrow	1	0.27%
33	within trianglesafety profilearrow icon	1	0.27%
34	rrmm in a singlearm	1	0.27%
35	of tecvayli® was evaluated	1	0.27%
36	patients with rrmm in	1	0.27%
37	approval for this indication	1	0.27%
38	an immunomodulatory agent and	1	0.27%
39	immunomodulatory agent and an	1	0.27%
40	agent and an anticd38	1	0.27%

#	URL	Whois	Check
1	https://www.tecvayli.com/	Whois	tecvayli.com
2	https://tec-talrems.com/#Main	Whois	tec-talrems.com
3	https://www.immunotherapy4myeloma.com/	Whois	immunotherapy4myeloma.com
4	https://www.tecvayli.com/	Whois	tecvayli.com
5	https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/TECVAYLI-pi.pdf	Whois	janssenlabels.com
6	https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/TECVAYLI-pi-es.pdf	Whois	janssenlabels.com
7	https://tec-talrems.com/#Main	Whois	tec-talrems.com
8	https://www.immunotherapy4myeloma.com/	Whois	immunotherapy4myeloma.com
9	https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-teclistamab-cqyv-relapsed-or-refractory-multiple-myeloma	Whois	fda.gov
10	https://www.janssen.com/oncology	Whois	janssen.com